SYDNEY, Nov 23, 2004 (BUSINESS WIRE) -- Australian Cancer Technology ("AustCancer") (ASX:ACU) today announced the appointment of Daniel C. Walding to the newly created position of Vice President, Sales and Marketing for its U.S.-based revisys(TM) medical nutritional supplements business.
"Dan brings to AustCancer more than 20 years of sales and marketing experience and joins us at a time when the seven-product line of revisys(TM) medical nutritionals is beginning to gain solid traction in the marketplace," said Paul Hopper, AustCancer's Managing Director. "With Dan on board we will further refine our marketing efforts and establish additional product distribution capabilities in the U.S. and abroad. Our feedback from the market is that there is a strong demand for scientifically credible nutritional products such as revisys(TM) and with Dan we now have the expertise to fully exploit that opportunity. We are delighted that he has joined our team and look forward to his many contributions." Hopper noted that since launching the product line in May 2004, the company has established relationships with three U.S.-based distributors and one based in Singapore for the revisys(TM) products.
Mr. Walding has deep sales and marketing management expertise garnered in the highly competitive electronic media industry. During his career he has built highly successful sales organizations and developed marketing promotions resulting in an associated revenue growth and increased market presence. He is a graduate of Rochester Institute of Technology and holds a bachelor of arts degree in managerial economics. Mr. Walding will be headquartered in Rochester, New York, U.S.A.
revisys(TM) is an integrated nutrient system that provides support for four levels of health and nutritional needs, from general well being to condition-specific supplementation. It is particularly designed for patients facing unique nutritional requirements due to extenuating health issues. Developed by leading medical scientists, revisys(TM) aims to become the leading choice of medical professionals for scientifically credible, high quality nutritional supplements.
About Australian Cancer Technology (www.austcancer.com.au)
Australian Cancer Technology (ASX:ACU) is a broadly based international oncology company developing a portfolio of high quality oncology-related projects that are at various stages of commercialisation. Its leading-edge Pentrys(TM) anti-cancer vaccine successfully completed Phase I and Phase I/IIa trials at St. Vincent's Hospital Sydney and is undergoing a comprehensive Phase IIb trial with prostate cancer patients at three leading Melbourne institutions. Its U.S. subsidiary, revisys(TM), has released a range of medical nutritionals designed by leading U.S. scientists for people with special needs, including those undergoing cancer treatments. The company acquired the U.S.-based Galenica Pharmaceuticals (renamed Adjuvantys(TM)), whose immune-enhancing adjuvants are being used in three Phase I and II cancer trials and will be used in a number of other forthcoming clinical trials in association with Memorial Sloan Kettering Cancer Centre in New York. AustCancer recently acquired the North American licence for the promising pancreatic cancer drug RP101, for which it is developing an accelerated clinical trial program, including application to the U.S. FDA for Orphan Drug status. The company is also collaborating with the U.S. company Bioaccelerate Inc. on the development of a prostate cancer drug which is expected to go into clinical trials in 2005. AustCancer has established a Level 1 ADR stock program in the U.S., trading under the code of "AUCJY," and has undertaken a secondary listing on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange, trading under the code "CBS."